56 results about "Mucosal tissue" patented technology

Modular mucosal tissue bioreactors combined with bioartificial mucus provide a high-fidelity, medium-throughput platform for evaluating CF treatments and modeling host-pathogen biology, a stepping stone towards better options for HEMT-nonresponsive patients. Whole lung ex vivo Cystic Fibrosis model system allows for investigation of candidate CF therapies.

The present invention provides a nutritional composition comprising one or more of vitamin D, polydextrose and galacto-oligosaccharides in combination with a calcium source. The composition has the effect of improving the intestinal mucosal barrier including improving intestinal mucosal permeability, modulating expression of intercellular tight junction proteins, improving intestinal mucosal tissue structure and improving levels of markers of the intestinal mucosal barrier.

The present invention provides compositions and methods of inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella typhi vector comprising a heterologous antigen from a pathogen, wherein the heterologous antigen comprises an outer membrane protein, an antigenic fragment thereof or a variant thereof, wherein the antigen is delivered to a mucosal tissue of the subject by an outer membrane vesicle.

This utility model relates to an orthodontic anchorage screw, which, from bottom to top, comprises a threaded section, a smooth section, a middle cap, a connecting rod section, and a top cap. The width of the connecting rod section is smaller than the width of the middle cap and the top cap at both ends. The middle cap, the connecting rod section, and the top cap form a groove for binding with a strap. The top cap is circular, with its top surface being an arched spherical surface with a smooth transition at the periphery, and its bottom surface also having a smooth transition at the periphery. The middle cap has a hexagonal prism-shaped portion. It is an orthodontic anchorage screw with a reasonable structure that reduces postoperative discomfort caused by friction between the intraoral anchorage screw and the mucosal tissue.

In some aspects, the disclosure relates to compositions and methods for skin repair and regeneration. In some embodiments, compositions described by the disclosure comprise natural products (e.g., extracts) combined with biotechnological excipient systems, such as bio surfactants, suitable for the repair of compromised skin, such as mucosal tissue (e.g., oral mucosal tissue).

The utility model relates to the technical field of medical balloons, in particular to a balloon device which comprises a catheter seat, a flexible catheter, a fixing ring and a balloon. One end of the flexible catheter is communicated with the catheter seat, the other end of the flexible catheter is fixedly connected with the fixing ring, the balloon is arranged on the side, away from the flexible catheter, of the fixing ring, and the flexible catheter is communicated with the balloon through a through hole in the fixing ring. Part of the balloon is attached to the circumferential contour of the fixing ring to form a connecting part, the balloon is fixedly connected with the fixing ring through the connecting part, and the balloon forms an expanding structure extending in the axial direction of the fixing ring after being expanded. In order to solve the technical problem that an existing ESD operation has defects, according to the balloon device, a catheter base is communicated with an external gas-liquid source, gas or liquid can be injected into a balloon through the catheter base so that the balloon can be filled, the filled balloon can eject pathological upper-layer mucous membrane tissue open, the lower layer of the mucous membrane can be exposed, and therefore the balloon device can be used for protecting the upper layer of the mucous membrane. Therefore, a doctor can conveniently perform stripping.

A method of treating an inflammatory condition in mucosal tissue of the airways of a subject, the method comprising locally contacting mucosal airway tissue of the subject with a microemulsion comprising a cannabinoid compound, and wherein the microemulsion when in a diluted form has a viscosity of 15cP or less, a surface tension of 45 mN / m or less and a hydrodynamic radius of 100 nm or less. Also a kit for treating an inflammatory condition in mucosal tissue of the airways in a subject, comprising (a) the microemulsion comprising the cannabinoid; and (b) a device for delivering the microemulsion to the mucosal tissue of the airways of the subject, wherein the device delivers the microemulsion in a liquid, spray, or aerosolized form.

The present invention discloses the use of a Chimonanthus dahurica leaf extract in preparing a drug for treating allergic rhinitis, and relates to the field of traditional Chinese medicine. Based on an allergic rhinitis animal model, the present invention investigates the effects of Chimonanthus dahurica leaves on the behavior, nasal mucosal tissue morphology, and serum inflammatory factor levels of AR rats, and clarifies the pharmacodynamics of Chimonanthus dahurica leaves in treating AR. That is, Chimonanthus dahurica leaves can significantly reduce the levels of IgE, histamine, ICAM-1, and inflammatory factors in the serum of rats with allergic rhinitis, and can also significantly improve the nasal mucosal symptoms of rats with allergic rhinitis, among which the Chimonanthus dahurica leaf water extract has a better effect. At the same time, by preparing different active component groups of Chimonanthus dahurica leaves, the effective parts of Chimonanthus dahurica for treating allergic rhinitis are screened, among which the 70% ethanol elution group and the 50% ethanol elution group have the best effects. The present invention has prospects for developing and preparing drugs for treating allergic rhinitis.

The present disclosure relates to methods and compositions for local expression of IL-12 in mucosal tissues, preferably in combination with an IFN-1 activator / inducer, for use in cancer immunotherapy.SOLUTION: The present invention solves the unmet need in the art for effective local expression of IL-12 using derivatized chitosan polyplexes reversibly coated with polyanion-containing block copolymers for potent transfection of mucosal tissues present in or proximal to tumors.SELECTED DRAWING: Figure 6

The present invention relates to iota-carrageenan for use as a main or sole active ingredient in an aqueous pharmaceutical composition for the prevention or treatment of non-viral non-allergic clinically relevant eye conditions affecting at least one of mucosal tissues at or around an individual's eye, an eye surface, corneal tissue, and fluid inside the eye, said clinically relevant eye conditions selected from the group consisting of increased intraocular pressure, non- allergic and non-viral conjunctivitis, irritations caused by airborne particulate matter other than allergens, and late complications of non-viral and non-allergic conjunctivitis selected from the group consisting of corneal opacities, subepithelial infiltrates, and formation of ocular pseudomembranes.

The present invention relates to a non-human mammal model of HSV latent infection, which enables detection of HSV in mucosal tissue upon exposure to a stimulus that reactivates latent HSV within the body. The non-human mammal according to the present invention can contribute to elucidating the mechanism of HSV latent infection and reactivation in humans and to developing drugs and the like for HSV.

A method of treating a soft palate in a patient may involve advancing a tissue treatment portion of a soft palate treatment device through the patient's mouth, contacting a treatment surface of the tissue treatment portion with mucosal tissue of the soft palate, and delivering energy from the tissue treatment portion through the mucosal tissue to a target tissue in the soft palate beneath to the mucosal tissue, to change at least one property of the target tissue. The method may further involve cooling the mucosal tissue with a cooling member on the treatment surface of the tissue treatment portion and removing the tissue treatment portion from the mouth.

The invention relates to a nanoparticle for use as a drug carrier and the synthesis method of this nanoparticle. In the invention, magnesium / aluminium (Mg / AI) mucoadhesive thiolated layered double hydroxide (nLDHT) nanoparticles are thiolated with L-cysteine and / or thioglycolic acid and / or 2-iminothiolane hydrochloride and / or glutathione and / or N-acetyl cysteine and / or 3-mercaptopropionic acid and / or 6- mercaptohexanoic acid. Thus, nLDHT interacts with the mucin on the surface of the targeted mucosal tissue for a longer period of time and acts with fewer side effects in the target tissues.

In some aspects, the disclosure relates to compositions and methods for skin repair and regeneration. In some embodiments, compositions described by the disclosure comprise natural products (e.g., extracts) combined with biotechnological excipient systems, such as biosurfactants, suitable for the repair of compromised skin, such as mucosal tissue (e.g., oral mucosal tissue).

The present inventions provide improved solution compositions and methods for detecting cancerous and dysplastic lesions in mucosal tissue in vivo. Specifically, the disclosed pretreatment solution results in enhanced removal of mucous and tissue debris. The disclosed detection solution compositions (nuclear stain-based and lectin-based) provide enhanced disease detection, when used individually or sequentially, tissue permeation, fluorescent signal, and shelf stability. Lectin fragmentation methods and processes of manufacturing are also disclosed. Additionally, various methods utilizes the disclosed inventive solution compositions are disclosed for accurate disease detection in vivo yielding high sensitivity and specificity values.

The invention discloses an oral vaccine as well as a preparation method and application thereof, and relates to the technical field of pharmaceutical preparations. The oral vaccine comprises a core, and a permeation enhancing layer, an active molecular layer and an enteric coating layer which are sequentially coated on the surface of the core, the core is a biodegradable polymer nano particle; the permeation enhancing layer is a polydopamine layer loaded with a permeation enhancer; the active molecular layer is a chitosan layer loaded with an antigen and a targeting substance. The oral vaccine provided by the embodiment of the invention is good in stability, can ensure that the antigen is stable in gastrointestinal tracts and keeps activity, realizes targeted release of intestinal tracts, can activate far-end mucous membrane tissues at the same time, realizes broad-spectrum IgA and IgG immunization, and is suitable for delivery of various oral antigens.

The application belongs to the technical field of biological medicine, and discloses a microneedle patch vaccine for inducing mucosal immune response and a preparation method and application thereof, specifically discloses a novel vaccine for inducing mucosal immune response, and the vaccine is delivered by a microneedle patch.The DNA nanoparticles wrapped by chitosan oligosaccharide are creatively combined with the microneedle technology, and it is proved that the strategy can induce a strong antigen-specific immune response in mucosal tissues such as lungs.The technology can be universally applied to the development of a novel mucosal vaccine for preventing mucosal route infectious pathogens (such as new coronavirus).

The invention features a mucosal coating composition including: (i) water: (ii) at least one mucoadhesive polymer / polysaccharide (e.g., a concentration between 0.1-20% w / v); and (iii) at least one surfactant (e.g., a concentration between 0.005-5% w / v). Exhibit long-lasting residence times on mucosal tissues and prophylactic protection against transmucosal pathogens.

The nasal septum is reshaped by creating multiple holes in the cartilage. RF energy can be applied to ablate tissue around the holes in a manner that minimizes damage of surrounding epithelial and mucosal tissues.

Hydrolyzed collagen compositions are described that are used for treatment of impaired tissue including mucosal tissue or to prevent damage to healthy tissue. These compositions function to treat mucosal tissues found in the digestive, urinary, respiratory and reproductive systems. Oral or topical, site-specific delivery of the compositions may be via liquid, spray, gel, powder, tablet, capsule, or sheet form.

The invention belongs to the technical field of biological medicine and cell therapy, and particularly relates to a preparation method of a human-derived nasal mucosa mesenchymal stem cell medicine for treating sepsis, which comprises the following steps: cell separation: taking adult nasal mucosa tissues, cutting into pieces, digesting with 0.25% pancreatin, and terminating digestion with a DF12 culture medium containing 20% serum; primary culture: after the tissue adheres to the wall for one week by using the first-step culture medium, replacing a DF12 culture medium containing 10% of serum, and after the cells climb out of the tissue, centrifugally collecting the cells for primary culture; 3, primary culture: identifying a fourth generation of cell surface marker in primary culture by flow cytometry, the invention reveals the deep mechanism of function enhancement of HuNMSCs by inhibiting cell autophagy, maintaining the integrity of a cell membrane structure and improving the survival rate of a sepsis model through molecular means such as lipid metabonomics and the like for the first time, and the deep mechanism of function enhancement of the HuNMSCs is illustrated by using the HuNMSCs to inhibit cell autophagy, maintain the integrity of a cell membrane structure and improve the survival rate of the sepsis model. The possibility of treating sepsis by HuNMSCs is clarified, a brand new cell treatment strategy is provided for sepsis, and a foundation is laid for subsequent clinical application.

Formulations comprising fenretinide, methods for the preparation of such formulations, systems (e.g., patches) comprising such formulations, as well as for their use as a secondary chemopreventive for precancerous lesions in the stratified squamous epithelium of mucosal tissue.

Provided are various formulations, which rapidly form into disulfide-linked hydrogels (e.g., PEG hydrogels) in 30 seconds or less. These rapidly forming hydrogels were also able to conform and adhere to mucosal tissues via PEG-mucin entanglements and hydrogen bonding. The crosslinked hydrogels are formed from disulfide exchange between a multivalent thiol component and a multivalent disulfide component. Also provided are methods of making and methods of using the crosslinked hydrogels.

This invention relates to the field of medical device technology and discloses an intestinal mucosal tissue oxygen saturation monitoring device, comprising a monitor body, a catheter, a balloon, a near-infrared spectral emission and detection device, a lead wire, an inflation tube, an inflation device, a partition, and tubing one and tubing two. This invention can be used to directly, objectively, and continuously assess changes in small intestinal mucosal microcirculation and tissue oxygen consumption, and can be applied in various clinical environments. Furthermore, it is based on jejunal catheter placement technology, a mature and technically simple technique that can be performed bedside and is suitable for use in primary hospitals and general wards.

A system for delivery of a therapeutic agent to a site in mucosal tissue is provided. The system includes a porous, mu- coadhesive polymeric matrix having a first and a second opposed surfaces. The matrix is formed by a composition including chitosan, a hydration promoter, a microparticle adhesion inhibitor, and a microparticle aggregation inhibitor. A plurality of micro- particles are embedded within the matrix. The microparticles contain a therapeutic agent and have a coating around the therapeutic agent. The first surface of the matrix is configured to be attached to the site in the mucosal tissue and the matrix is configured to provide controlled release of the microparticles through the first surface. The coating of the microparticles includes chitosan so as to provide controlled release of the agent from the microparticles.

The invention relates to an oxygen-assisted in-situ crosslinking strong-adhesion gel system and application thereof in mucosa protection, and belongs to the field of biomedical material engineering. The gel system comprises carboxymethyl chitosan, genipin and hydrogen peroxide, carboxymethyl chitosan is used as a monomer, genipin is used as a cross-linking agent, and hydrogen peroxide is used as a triggering agent. The genipin can be cross-linked with amino groups in the carboxymethyl chitosan, so that the gel is subjected to in-situ cross-linking; genipin can be covalently bound with amino on the surface of the tissue at the same time, so that the gel mucosa is endowed with a strong adhesion characteristic; the hydrogen peroxide can be catalytically decomposed by peroxidase on the surface of the mucosal tissue to generate oxygen, and the reaction is triggered. The gel system disclosed by the invention can be smeared on the surface of a mucosa, oxygen generated by catalysis of biological enzyme on the surface of the mucosa triggers in-situ rapid crosslinking of the gel, the gel is firmly adhered to the mucosa, a protective isolation coating is formed on the surface of the mucosa, and stimulation of harmful ingredients in digestive juice to the mucosa is prevented.

This present invention relates to the use of eicosapentaenoic acid (EPA) for the treatment of ulcerative colitis (UC), and more particularly, the use of highly purified eicosapentaenoic acid as free fatty acids (EPA-FFA) having a purity of at least 95% for reducing inflammation in a subject suffering from ulcerative colitis and wherein the levels of IL-10 and SOCS3 are increased and the microbiome of the intestinal mucosal tissue is favorably modulated.

A system is disclosed for delivery of a therapeutic agent to a site in mucosal tissue or to the skin of a patient. The system includes a porous mucoadhesive, freeze-dried matrix formed by a composition including chitosan in an aqueous salt solution of a chloride salt of a monovalent cation. The system further includes a plurality of chitosan microparticles having an average diameter between 500 nm and 2000 nm and comprising a therapeutic agent.

To provide therapeutic agents that can increase protection or mitigate of the effects of exposure to ionizing radiation useful for increasing the survival of normal cellular, tissue, organ and system and restoration of these functions after accidental exposure to ionizing radiation or in a radiation therapy setting.SOLUTION: Provided is a pharmaceutical composition for protecting a subject after exposure to radiation, the subject being undergoing radiation therapy for head and neck cancer, and the pharmaceutical composition comprising a therapeutically effective amount of substantially isolated rIL-12, thereby reducing radiation-induced damage to one or more of the subject's immune system, gastrointestinal system, and mucosal tissue.SELECTED DRAWING: Figure 2

The present application belongs to the technical field of nutritional health food, and particularly relates to a composition for repairing oral mucosa and a preparation method and application thereof. The composition comprises, by weight of the composition: 2%-80% of yeast beta glucan, 0.5%-50% of lactobacillus salivarius powder, 0.5%-50% of lactobacillus acidophilus powder, and 0.5%-50% of paracasei lactobacillus powder. The composition for repairing oral mucosa and the auxiliary materials are further prepared into a functional food in the form of tablets, liquids, soft candies or powders. In the functional food, the composition as the main component plays a role in repairing and preventing damage to the oral mucosa. Meanwhile, the composition and the auxiliary materials are dissolved under the action of oral saliva enzymes, thereby fully contacting the oral mucosa and pathogens and emitting a sweet and sour taste, so as to bring a pleasant sensory experience to the oral cavity.